{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:07:07Z","timestamp":1792174027983,"version":"4.4.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100013595","name":"AMAG Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.bioorg.2025.108204","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T19:00:39Z","timestamp":1737745239000},"page":"108204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Isoxazole-pyrimidine derivatives as TACC3 inhibitors: A novel modality to targeted cancer therapy"],"prefix":"10.1016","volume":"156","author":[{"given":"Deniz","family":"Lengerli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zge Akbulut","family":"\u00c7al\u0131\u015fkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00fcbra","family":"\u00c7al\u0131\u015fkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zge","family":"Saatci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaemin","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridhar","family":"Vempati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcu","family":"\u00c7al\u0131\u015fkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zg\u00fcr","family":"\u015eahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erden","family":"Banoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bioorg.2025.108204_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcb.2020.151075","article-title":"Microtubule-targeting agents and their impact on cancer treatment","volume":"99","author":"Cermak","year":"2020","journal-title":"Eur. J. Cell Biol."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108204_b0010","first-page":"164","article-title":"New insights into mechanisms of resistance to microtubule inhibitors","volume":"1816","author":"Ganguly","year":"2011","journal-title":"BBA"},{"issue":"1\u20132","key":"10.1016\/j.bioorg.2025.108204_b0015","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10555-009-9185-8","article-title":"Kinesin motor proteins as targets for cancer therapy","volume":"28","author":"Huszar","year":"2009","journal-title":"Cancer Metastasis Rev."},{"issue":"12","key":"10.1016\/j.bioorg.2025.108204_b0020","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1080\/13543784.2019.1694661","article-title":"Investigational CHK1 inhibitors in early phase clinical trials for the treatment of cancer","volume":"28","author":"Dent","year":"2019","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"14","key":"10.1016\/j.bioorg.2025.108204_b0025","doi-asserted-by":"crossref","first-page":"23937","DOI":"10.18632\/oncotarget.14893","article-title":"Aurora kinases: novel therapy targets in cancers","volume":"8","author":"Tang","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.bioorg.2025.108204_b0030","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/2162-3619-1-38","article-title":"Polo-like kinase 1 as target for cancer therapy","volume":"1","author":"Weiss","year":"2012","journal-title":"Exp. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108204_b0035","doi-asserted-by":"crossref","first-page":"105","DOI":"10.4161\/bioa.1.3.16518","article-title":"Pulling it together: The mitotic function of TACC3","volume":"1","author":"Hood","year":"2011","journal-title":"BioArchitecture"},{"issue":"21","key":"10.1016\/j.bioorg.2025.108204_b0040","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1091\/mbc.e14-06-1121","article-title":"TACC3 is a microtubule plus end-tracking protein that promotes axon elongation and also regulates microtubule plus end dynamics in multiple embryonic cell types","volume":"25","author":"Nwagbara","year":"2014","journal-title":"Mol. Biol. Cell"},{"issue":"46","key":"10.1016\/j.bioorg.2025.108204_b0045","doi-asserted-by":"crossref","first-page":"31719","DOI":"10.1074\/jbc.M114.575100","article-title":"TACC3 protein regulates microtubule nucleation by affecting gamma-tubulin ring complexes","volume":"289","author":"Singh","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2025.108204_b0050","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/cm.21388","article-title":"The role of TACC3 in mitotic spindle organization","volume":"74","author":"Ding","year":"2017","journal-title":"Cytoskeleton (hoboken)"},{"issue":"1","key":"10.1016\/j.bioorg.2025.108204_b0055","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.canlet.2013.04.022","article-title":"Transforming acidic coiled-coil proteins (TACCs) in human cancer","volume":"336","author":"Ha","year":"2013","journal-title":"Cancer Lett."},{"issue":"13","key":"10.1016\/j.bioorg.2025.108204_b0060","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1038\/onc.2014.105","article-title":"TACC3 deregulates the DNA damage response and confers sensitivity to radiation and PARP inhibition","volume":"34","author":"Ha","year":"2015","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.bioorg.2025.108204_b0065","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.21873\/anticanres.15123","article-title":"TACC3 Promotes Gastric Carcinogenesis by Promoting Epithelial-mesenchymal Transition Through the ERK\/Akt\/cyclin D1 Signaling Pathway","volume":"41","author":"Akanda","year":"2021","journal-title":"Anticancer Res"},{"issue":"6","key":"10.1016\/j.bioorg.2025.108204_b0070","doi-asserted-by":"crossref","first-page":"8541","DOI":"10.18632\/aging.202668","article-title":"TACC3 is a prognostic biomarker for kidney renal clear cell carcinoma and correlates with immune cell infiltration and T cell exhaustion","volume":"13","author":"Fan","year":"2021","journal-title":"Aging (Albany NY)"},{"issue":"2","key":"10.1016\/j.bioorg.2025.108204_b0075","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3727\/096504017X14837020772250","article-title":"Knockdown of TACC3 Inhibits the Proliferation and Invasion of Human Renal Cell Carcinoma Cells","volume":"26","author":"Guo","year":"2018","journal-title":"Oncol. Res."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108204_b0080","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.bbrc.2017.03.090","article-title":"Overexpression of TACC3 is correlated with tumor aggressiveness and poor prognosis in prostate cancer","volume":"486","author":"Li","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"9","key":"10.1016\/j.bioorg.2025.108204_b0085","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1097\/CORR.0000000000000379","article-title":"Elevated Expression of Transforming Acidic Coiled-Coil Containing Protein 3 (TACC3) Is Associated With a Poor Prognosis in Osteosarcoma","volume":"476","author":"Matsuda","year":"2018","journal-title":"Clin. Orthop. Relat. Res."},{"issue":"9","key":"10.1016\/j.bioorg.2025.108204_b0090","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1097\/CORR.0000000000000416","article-title":"CORR Insights(R): Elevated Expression of Transforming Acidic Coiled-Coil Containing Protein 3 (TACC3) Is Associated With a Poor Prognosis in Osteosarcoma","volume":"476","author":"Morawietz","year":"2018","journal-title":"Clin. Orthop. Relat. Res."},{"issue":"6","key":"10.1016\/j.bioorg.2025.108204_b0095","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/ijlh.13289","article-title":"TACC3 expression as a prognostic factor in aggressive types of adult T-cell leukemia\/lymphoma patients","volume":"42","author":"Moritsubo","year":"2020","journal-title":"Int. J. Lab. Hematol."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108204_b0100","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s10020-021-00298-z","article-title":"Transforming acidic coiled-coil protein-3: a novel marker for differential diagnosis and prognosis prediction in endocervical adenocarcinoma","volume":"27","author":"Wen","year":"2021","journal-title":"Mol. Med."},{"issue":"27","key":"10.1016\/j.bioorg.2025.108204_b0105","doi-asserted-by":"crossref","first-page":"24163","DOI":"10.18632\/oncotarget.4643","article-title":"TACC3 promotes stemness and is a potential therapeutic target in hepatocellular carcinoma","volume":"6","author":"Zhou","year":"2015","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.bioorg.2025.108204_b0110","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.bbrc.2018.03.125","article-title":"Inhibition of TACC3 by a small molecule inhibitor in breast cancer","volume":"498","author":"Campo","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"454","key":"10.1016\/j.bioorg.2025.108204_b0115","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar2718","article-title":"KHS101 disrupts energy metabolism in human glioblastoma cells and reduces tumor growth in mice","volume":"10","author":"Polson","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108204_b0120","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41389-017-0018-2","article-title":"Novel therapeutic strategy for cervical cancer harboring FGFR3-TACC3 fusions","volume":"7","author":"Tamura","year":"2018","journal-title":"Oncogenesis"},{"issue":"38","key":"10.1016\/j.bioorg.2025.108204_b0125","doi-asserted-by":"crossref","first-page":"16542","DOI":"10.1073\/pnas.1010300107","article-title":"A small molecule accelerates neuronal differentiation in the adult rat","volume":"107","author":"Wurdak","year":"2010","journal-title":"PNAS"},{"key":"10.1016\/j.bioorg.2025.108204_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114874","article-title":"Discovery of novel analogs of KHS101 as transforming acidic coiled coil containing protein 3 (TACC3) inhibitors for the treatment of glioblastoma","volume":"244","author":"Zhao","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"33","key":"10.1016\/j.bioorg.2025.108204_b0135","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1038\/onc.2013.382","article-title":"A small compound targeting TACC3 revealed its different spatiotemporal contributions for spindle assembly in cancer cells","volume":"33","author":"Yao","year":"2014","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.bioorg.2025.108204_b0140","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1158\/1535-7163.MCT-19-0957","article-title":"A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate","volume":"19","author":"Akbulut","year":"2020","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108204_b0145","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s41418-023-01140-1","article-title":"Targeting TACC3 represents a novel vulnerability in highly aggressive breast cancers with centrosome amplification","volume":"30","author":"Saatci","year":"2023","journal-title":"Cell Death Differ."},{"issue":"9","key":"10.1016\/j.bioorg.2025.108204_b0150","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1158\/0008-5472.CAN-23-2812","article-title":"Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast Cancer","volume":"84","author":"Gedik","year":"2024","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.bioorg.2025.108204_b0155","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3987\/COM-91-5712","article-title":"Practical Synthesis of 3-Amino-5-Tert-Butylisoxazole from 4,4-Dimethyl-3-Oxopentanenitrile with Hydroxylamine","volume":"32","author":"Takase","year":"1991","journal-title":"Heterocycles"},{"issue":"3","key":"10.1016\/j.bioorg.2025.108204_b0160","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1021\/jm2009925","volume":"55","author":"Rowbottom","year":"2012","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108204_b0165","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1021\/acs.joc.8b02986","article-title":"Reactions of 5-Aminoisoxazoles with alpha-Diazocarbonyl Compounds: Wolff Rearrangement vs N-H Insertion","volume":"84","author":"Ge","year":"2019","journal-title":"J. Org. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2025.108204_b0170","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1134\/S1070428010080191","article-title":"Amination of 4,6-and 2,4-Dichloropyrimidines with Polyamines","volume":"46","author":"Kobelev","year":"2010","journal-title":"Russ. J. Org. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2025.108204_b0175","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1039\/p19920000919","article-title":"Reaction of N-substituted cyclic amines with 2,4-dichloroquinazoline, 2,4-dichloropyrimidine, and its 5-methyl derivative","volume":"1","author":"Yoshida","year":"1992","journal-title":"J. Chem. Soc. Perkin Trans."},{"key":"10.1016\/j.bioorg.2025.108204_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112141","article-title":"Design, synthesis and evaluation of phenylthiazole and phenylthiophene pyrimidindiamine derivatives targeting the bacterial membrane","volume":"190","author":"Fan","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"13","key":"10.1016\/j.bioorg.2025.108204_b0185","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1055\/s-0033-1338853","article-title":"Chemoselective Reactions of 4,6-Dichloro-2-(methylsulfonyl)pyrimidine and Related Electrophiles with Amines","volume":"45","author":"Baiazitov","year":"2013","journal-title":"Synthesis-Stuttgart"},{"issue":"35","key":"10.1016\/j.bioorg.2025.108204_b0190","doi-asserted-by":"crossref","first-page":"10569","DOI":"10.1002\/anie.201705525","article-title":"Mechanistic Insight Leads to a Ligand Which Facilitates the Palladium-Catalyzed Formation of 2-(Hetero)Arylaminooxazoles and 4-(Hetero)Arylaminothiazoles","volume":"56","author":"Olsen","year":"2017","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"14","key":"10.1016\/j.bioorg.2025.108204_b0195","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1002\/anie.201300763","article-title":"Direct Synthesis of Fluorinated Heteroarylether Bioisosteres","volume":"52","author":"Zhou","year":"2013","journal-title":"Angewandte Chemie-Int. Ed."},{"issue":"19","key":"10.1016\/j.bioorg.2025.108204_b0200","doi-asserted-by":"crossref","first-page":"14046","DOI":"10.1021\/acs.jmedchem.1c01215","article-title":"Bioisosteres of the Phenyl Ring: Recent Strategic Applications in Lead Optimization and Drug Design","volume":"64","author":"Subbaiah","year":"2021","journal-title":"J. Med. Chem."},{"issue":"14","key":"10.1016\/j.bioorg.2025.108204_b0205","doi-asserted-by":"crossref","first-page":"5822","DOI":"10.1021\/acs.jmedchem.7b01788","article-title":"Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design","volume":"61","author":"Meanwell","year":"2018","journal-title":"J. Med. Chem."},{"issue":"22","key":"10.1016\/j.bioorg.2025.108204_b0210","doi-asserted-by":"crossref","first-page":"13595","DOI":"10.1021\/acs.jmedchem.0c00620","article-title":"4-(Difluoromethyl)-5-(4-((3R,5S)-3,5-dimethylmorpholino)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders","volume":"63","author":"Borsari","year":"2020","journal-title":"J. Med. Chem."},{"issue":"19","key":"10.1016\/j.bioorg.2025.108204_b0215","doi-asserted-by":"crossref","first-page":"8934","DOI":"10.1021\/acs.jmedchem.8b01148","article-title":"Lowering Lipophilicity by Adding Carbon: One-Carbon Bridges of Morpholines and Piperazines","volume":"61","author":"Degorce","year":"2018","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108204_b0220","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/9780470559277.ch110180","article-title":"Target identification using drug affinity responsive target stability (DARTS)","volume":"3","author":"Lomenick","year":"2011","journal-title":"Curr Protoc Chem Biol"},{"issue":"23\u201324","key":"10.1016\/j.bioorg.2025.108204_b0225","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1080\/15384101.2024.2302243","article-title":"TACC3: a multi-functional protein promoting cancer cell survival and aggressiveness","volume":"22","author":"Saatci","year":"2023","journal-title":"Cell Cycle"},{"issue":"2","key":"10.1016\/j.bioorg.2025.108204_b0230","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10549-022-06569-5","article-title":"Targeting HIF1-alpha\/miR-326\/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer","volume":"193","author":"Assidicky","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108204_b0235","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1038\/s41467-020-16199-4","article-title":"Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer","volume":"11","author":"Saatci","year":"2020","journal-title":"Nat. Commun."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825000847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825000847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T02:03:33Z","timestamp":1758852213000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825000847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":47,"alternative-id":["S0045206825000847"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108204","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Isoxazole-pyrimidine derivatives as TACC3 inhibitors: A novel modality to targeted cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108204","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108204"}}